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A comparison of viral microneutralization and haemagglutination inhibition assays 1 
as measures of seasonal inactivated influenza vaccine immunogenicity in the first 2 
year after reduced intensity conditioning, lymphocyte depleted allogeneic 3 
haematopoietic stem cell transplant. 4 
Miller PDE, de Silva TI, Leonard H, Anthias C, Hoschler K, Goddard K, Peggs K, 5 
Madrigal A, Snowden JA. 6 
Introduction 7 
Respiratory viruses (RV) are identified in approximately 3.5% of haematopoietic stem 8 
cell transplant (HSCT) recipients.  Influenza A and B viruses account for 18-44% of RV 9 
infections [1,2].  Patients transplanted during the influenza season are at highest risk 10 
of infection.  Progression to pneumonia occurs more frequently in the early post-11 
HSCT period and is associated with a 30-day mortality rate up to 28% [3,4]. Annual 12 
administration of a seasonal inactivated influenza vaccine (SIIV) is considered a 13 
moderately effective strategy for prevention of infection and influenza-associated 14 
hospital admission in the general population[5]; vaccine effectiveness ranging from 15 
19-60% across all age groups has been estimated in the United States over the last 16 
decade[6,7].  Vaccine efficacy of 65.4-80% has been reported in HSCT patients, 17 
although in small cohorts [8,9], and current guidelines for influenza vaccination of 18 
HSCT recipients are largely based on immunogenicity studies. 19 
Historically, the European Medicines Agency (EMA) Committee for Medicinal 20 
Products for Human Use (CHMP) immunogenicity criteria for annual SIIV licensing 21 
have focussed primarily on rates of seroconversion (defined as a fourfold increase in 22 
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antibody (Ab) titre from baseline) and seroprotection (an Ab ƚŝƚƌĞA? ? ? ?ĚĞƚĞĐƚĞĚďǇ23 
serological haemagglutination inhibition (HAI) techniques[10].  Studies in HSCT 24 
populations evaluating response to SIIV against CHMP criteria have reported minimal 25 
immunogenicity when administered in the first 6 months post-HSCT and impaired 26 
response up to at least 12 months post-HSCT[11 ?13]. So, although HSCT recipients in 27 
the early post-HSCT are at high risk of influenza related morbidity and mortality, 28 
especially if transplanted during the influenza season, current evidence is insufficient 29 
to recommend SIIV administration before at least 4 to 6 months post-HSCT [14,15]. 30 
However, in practice a proportion of allogeneic HSCT centres in the United Kingdom 31 
(UK) administer the influenza vaccine at earlier time points[16].   Current guidelines 32 
do not recommend modification of vaccination schedules according to underlying 33 
disease, conditioning intensity, graft manipulation or stem cell source.     34 
A growing body of evidence argues that an HAI Ab tŝƚƌĞA? ? ?may not be 35 
seroprotective in population subgroups, and suggests that probability of protection 36 
may be better considered along a continuum of titres rather than against this cut-off 37 
value[17 ?19].  In 2016, the CHMP immunogenicity criteria were updated to reflect 38 
this, and now a more diverse range of assessment methods of SIIV immune 39 
responses including neutralizing Ab titres are recommended [20]. The virus 40 
microneutralization (VMN) assay is a highly sensitive and specific method for 41 
detecting influenza strain-specific, functional antibodies that inhibit virus entry or 42 
block virus replication[21].  The VMN has higher sensitivity than HAI for the 43 
detection of low-titre seroconversion particularly to influenza B[22,23] and 2009 44 
pandemic H1N1 virus[24].  Ab titres detectable by VMN assay may confer clinical 45 
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protection against influenza virus, although titres have not yet been correlated with 46 
clinical efficacy.  To our knowledge, the VMN has not previously been used to 47 
determine SIIV response in HSCT recipients. 48 
The primary aim of this study was to assess, by HAI and VMN techniques, the 49 
immunogenicity of SIIV administered within the first 12 months in a homogenous 50 
cohort of reduced intensity conditioning (RIC) peripheral blood stem cell (PBSC) HSCT 51 
recipients. The secondary aim was to determine whether in patients vaccinated at 52 
less than 3 months, a response is detectable by VMN.   53 
 54 
 55 
Materials and Methods 56 
Participants 57 
Participants were screened for study eligibility during routine outpatient clinic 58 
appointments between October 2015 and February 2016.  Eligible participants were 59 
aged 16 or over, and recipients of reduced intensity conditioning (RIC) peripheral 60 
blood stem cell (PBSC) alloHSCT within 0 and 12 months of transplant.  All 61 
participants were vaccinated in accordance with standards of care at their transplant 62 
centre and were deemed suitable to receive the SIIV by their lead transplant 63 
physician.  Standard of care at one study centre was to vaccinate from 3 months 64 
post-HSCT, while at the other, vaccination was offered at the beginning of the 65 
influenza season regardless of time-point post-HSCT.  All patients gave written 66 
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informed consent.  The study was approved by the Health Research Authority 67 
National Research Ethics Committee of the UK (Reference 15/YH/0394).  68 
 69 
Vaccination and Blood Samples 70 
Patients received in the deltoid muscle, a single injection of a split virion, trivalent 71 
2015-2016 northern hemisphere SIIV (Sanofi-Pasteur, Guildford, UK), containing 72 
15µg haemagglutinin (HA) of each of A/California/7/2009(H1N1)pdm09, 73 
A/Switzerland/9715293/2013(H3N2) and B/Phuket/3073/2013. Blood samples were 74 
collected at recruitment prior to vaccination, and at approximately four weeks post-75 
vaccination. Serum samples were stored at -2 ?຀°C until analysis.   76 
 77 
Viruses, erythrocytes and cell culture 78 
For VMN assays, live, egg-grown influenza A/California/7/2009(H1N1)pdm09, 79 
influenza A/Switzerland/9715293/2013(H3N2) and influenza B/Phuket/3073/2013 80 
(Public Health England, London, UK) were used. HAI assays used the same live, egg-81 
grown influenza A viruses, but ether-treated influenza B virus (Public Health 82 
England).  A 0.5% solution of turkey erythrocytes in phosphate buffered saline (PBS) 83 
(Gibco, Hemel Hempstead, UK) for A(H1N1)pmd09 and B(Phuket), or guinea-pig 84 
erythrocytes, for A(H3N2), were used in HAI assays.  All VMN assays used Madin-85 
Darby canine kidney (MDCK)(Public Health England, London, UK) cells cultured in 86 
ĂƌůĞ ?ƐDŝŶŝŵƵŵƐƐĞŶƚŝĂůDĞĚŝƵŵ ?DD ?ǁŝƚŚ4-(2-hydroxyethyl)-1-87 
piperazineethanesulfonic acid (HEPES) and L-Glutamine (Gibco), and supplemented 88 
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with 0.5mg/ml gentamycin, non-essential amino acids solution (Gibco) and 10% fetal 89 
calf serum (FCS) (Gibco).  90 
 91 
Haemagglutination Inhibition (HAI) and Viral Miconeutralisation (VMN) Assays  92 
All assays were performed in the Public Health England (PHE) respiratory virus 93 
reference laboratory.  For each of A(H1N1)pdm09, A(H3N2) and B(Phuket), an HAI as 94 
previously described [25], and a 3-day VMN assay with modified cytopathic effect 95 
(CPE) endpoint, were performed on paired pre- and post-vaccination serum samples. 96 
In addition, for A(H1N1)pdm09 a 2-day VMN enzyme-linked immunosorbent (ELISA) 97 
assay was performed.  In brief, for the CPE-VMN, serum samples heat treated at 56°C 98 
for 30 minutes were diluted to 1:10 with PBS followed by serial doubling dilutions 99 
across a 96-well u-bottom plate to a dilution of 1:5120. Live egg-grown virus solution 100 
(Public Health England, London, UK) standardized to 100x50% tissue culture infective 101 
dose/ml (TCID50) was added to each well containing serum, and incubated at 37°C in 102 
5% humidified CO2 atmosphere for 60 minutes.  After incubation, confluent MDCK  103 
cells in a 96-well culture plate were inoculated with serum-virus mixture, and viral 104 
growth medium (VGM) consisting of serum-free, modified Eagle Medium (SF-105 
MEM)(Gibco, Hemel Hempstead, UK), and 1µg/ml Tosyl-phenylalanyl-chloromethyl-106 
ketone(TPCK) treated Trypsin(Sigma, Gillingham, UK) was added.  Inoculated cell 107 
culture plates were incubated for either 2 hours (influenza A viruses) or 3 hours 108 
(influenza B virus) at 37°C in 5% humidified CO2 atmosphere.  Virus-serum inoculum 109 
was then aspirated, and each well rinsed twice with 200µl SF-MEM.  one-hundred 110 
and fifty microlitres VGM (1.0µg/ml for influenza A viruses, 1.5µg/ml for influenza B 111 
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virus) was added to wells inoculated with virus, and plates were incubated at 37C°C 112 
in 5% humidified CO2 atmosphere (70 hours for influenza A viruses, 46 hours for 113 
influenza B virus).   Fifty microlitres of cell supernatant was transferred to 114 
corresponding wells of a 96 well v-bottom plate and tested for influenza virus by HA 115 
assay.  Ab titres were recorded as the reciprocal of the highest dilution at which 116 
agglutination was absent.  For the A(H1N1)pdm09 ELISA-VMN a virus-serum mixture 117 
was prepared as above and added to a 96-well culture plate.   After incubation at 118 
37°C in 5% humidified CO2 atmosphere for 60 minutes, a 5x105 cell/ml MDCK cell 119 
suspension was added to each well.   Plates were then incubated for 16 hours at 120 
37°C in 5% humidified CO2 atmosphere.  An ELISA was then performed as previously 121 
described[26] .  122 
 123 
Statistical Analysis 124 
Continuous variables are reported as median values with ranges.  Categorical 125 
variables are reported as frequencies and percentages. Immunological data is 126 
summarised as pre- and post-vaccination geometric mean titres (GMT), and 127 
geometric mean ratios (GMRs) of pre- and post-vaccination titres with 95% 128 
confidence intervals. The distribution of Ab titre values was not Gaussian, so paired 129 
results were compared with the Wilcoxon signed-rank test for non-parametric data.  130 
Correlation between GMT and GMRs, and continuous explanatory variables were 131 
ĞǆƉůŽƌĞĚǁŝƚŚ^ƉĞĂƌŵĂŶ ?ƐZĂŶŬŽƌƌĞůĂƚŝŽŶ ?ĨŽƌcategorical explanatory variables 132 
Mann-Whitney test ǁĂƐƵƐĞĚ ?&ƌĞƋƵĞŶĐŝĞƐŽĨƐĞƌŽĐŽŶǀĞƌƐŝŽŶĂŶĚ,/ďƚŝ ƌĞƐA? ? ?133 
are reported, and the relationship between these outcome measures and categorical 134 
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explanatory variables was ĞǆƉůŽƌĞĚǁŝƚŚWĞĂƌƐŽŶ ?ƐŚŝ-^ƋƵĂƌĞƚĞƐƚ ?Žƌ&ŝƐŚĞƌ ?ƐĞǆĂĐƚ135 
test; binary logistic regression was used for continuous explanatory variables.  The 136 
relationship between log10 transformed HAI and VMN titres was explored using a 137 
linear regression model.  Analysis was performed with IBM SPSS version 24.   138 
 139 
 140 
 141 
Results 142 
Study Population 143 
Twenty-eight alloHSCT recipients with a median age of 57.8 (range 38.0-72.1) years 144 
were recruited for the study (Table 1).   Participants were vaccinated at a median 145 
time-point of 78.5 (range 24-363) days after HSCT, and all 28 gave post-vaccination 146 
blood samples at a median of 28 days (range 21-50).  All but 1/28 patients provided 147 
their sample within the 21  ? 28 day window. Donor type was volunteer unrelated 148 
donor (VUD) in 71.4% of HSCTs, and sibling in 28.6%. All conditioning regimens 149 
included in-vivo lymphocyte depletion with alemtuzumab (89.3%) or antithymocyte 150 
globulin (ATG) (10.7%).  Graft-versus-host disease (GvHD) was presnt in 28.6% of 151 
participants, which was limited to stage 1 acute skin GVHD(17.9%) or mild chronic 152 
skin GVHD (10.7%) in all cases.  A minority of of participants had been treated with 153 
rituximab (10.7%) or intravenous immunoglobulin (7.1%) in the last 12 months.   154 
 155 
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SIIV Immunogenicity 156 
Geometric mean titres (GMT) and geometric mean ratios (GMR)  157 
GMTs and GMRs of pre- and post-vaccination titres of A(H1N1)pdm09, A(H3N2) and 158 
B(Phuket) Ab are shown in Table 2.  The GMTs of A(H1N1)pdm09 and A(H3N2) Ab 159 
were higher by CPE-VMN than HAI,  and A(H1N1) GMTs were higher by ELISA-VMN 160 
than CPE-VMN,  at both pre- and post-vaccination timepoints.  However, none of the 161 
three assays detected a significant change in Ab titre following vaccination, as 162 
reflected in GMRs of pre- and post-vaccination Ab titres close to 1.  In contrast, 163 
B(Phuket) GMTs were higher by HAI than CPE-VMN at both pre- and post-vaccination 164 
timepoints.  Despite vaccination, there was a statistically significant decline in 165 
B(Phuket)-specific Ab titres from pre- to post- vaccination by both HAI (15.17 v 166 
11.89, p=0.017) and CPE-VMN (6.98 v 6.25, p=0.018) with similar GMRs of 0.78 (95% 167 
CI 0.62-0.94) and 0.89 (0.82-0.96) by both assays.  168 
 169 
Frequency of detectable Ab titres and frequency of seroconversions 170 
Considering both pre- and post-vaccination values, 25/56 (44.6%) serum samples had 171 
detectable Ab against H1N1(pdm09) by HAI compared with 31 (55.4%) by CPE-VMN 172 
and 38 (67.9%) by ELISA-VMN.  For H3N2, 32 (57.1%) serum samples had detectable 173 
Ab by HAI versus 54 (96.4%) by VMN, while for B(Phuket) equivalent values are 27  174 
(48.2%) by HAI versus 12 (21.4%) by VMN.  No seroconversions to any vaccine 175 
component were detected by HAI assay or CPE-VMN.  A single seroconversion was 176 
detected by ELISA-VMN in a patient vaccinated at 9 weeks post-HSCT.   177 
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 178 
HAI  ƚŝƚƌĞƐш ? ? 179 
The frequency of patients with HAI ďƚŝƚƌĞƐA? ? ? are displayed by vaccination time-180 
point in Table 3.  Pre-vaccination,  ? ?A?ŽĨƉĂƌƚŝĐŝƉĂŶƚƐŚĂĚ,/ďƚŝƚƌĞƐA? ? ? against 181 
any single vaccine component.  &ƌĞƋƵĞŶĐǇŽĨ,/ďƚŝƚƌĞA? ? ?ǁĂƐŚŝŐŚĞƐƚŝŶƚŚŽƐĞ182 
vaccinated at 0-3 months (60.0%) and lowest at 6-12 months (28.6%) although this 183 
trend was not statistically significant (p=0.39).  As seroprotective titres for CPE and 184 
ELISA-VMN have not been defined, equivalent data are not presented for these 185 
assays. 186 
 187 
Relationship between HAI and VMN titres 188 
Statistically significant correlation was observed between HAI and VMN titres for all 189 
3 strains (p<0.001).  From the linear regression equation, CPE-VMN titres equivalent 190 
to an HAI titre of 40 were estimated as 65.18 (95%CI 42.33-100.36) for 191 
A(H1N1)pdm09, 366.77 (95% CI 105.41-1276.12) for A(H3N2), and 10.17 (95% CI 192 
7.74-13.36) for B(Phuket).  For A(H1N1)pdm09, the ELISA-VMN titre equivalent to an 193 
HAI titre of 40 was 164.10 (95% CI 86.37-311.78). 194 
 195 
Discussion 196 
In this study, the immunogenicity of the 2015-2016 SIIV was evaluated in HSCT 197 
recipients using the HAI and VMN assays.  This is the first study to report VMN data 198 
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in this patient group.  A limitation of this study is that it did not include a comparator 199 
arm of immunocompetent participants.   200 
GMTs for A(H1N1)pdm09 and A(H3N2) determined by VMN were statistically 201 
significantly higher than by HAI,  suggesting VMN may provide a more sensitive assay 202 
to detect influenza-specific antibody titres in this population. The estimated VMN 203 
equivalent of an HAI titre of 40 was 65.18 (95% CI 42.33-100.36) for CPE endpoint 204 
and 164.10 for ELISA endpoint .  Previous studies of H1N1(A/Brisbane/59/2007) in a 205 
paediatric population,  and A(H1N1)pdm09 in a healthy adult population using an 206 
ELISA-based VMN, estimated that titres of 200 and 211 respectively were equivalent 207 
to an HAI titre of 40[27,28].  The same paediatric study estimated that VMN titre of 208 
140 was equivalent to HAI titre of 40 for H3N2(A/Brisbane/10/2007).  In a small 209 
study of patients infected by H3N2(A/SouthAfrica/114/95/7), GMTs by HAI and 210 
ELISA-based VMN were 29.19 and 362.98 respectively[29].  The comparative 211 
A(H3N2) HAI and VMN titres in this present study are similar to these previous 212 
findings, while for A(H1N1)pdm09 our estimate is lower.  For A(H1N1)pdm09, an 213 
ELISA-based VMN appears to offer greater sensitivity than a CPE-VMN for detection 214 
of strain-specific Ab.  A(H3N2) viruses have been the dominant circulating strains and 215 
a component of the SIIV since at least 1998[30], while the A(H1N1)pdm09 virus is by 216 
definition antigenically dissimilar to H1N1 strains preceding 2009.  The presence of 217 
cross-reacting neutralizing Ab to A(H3N2) from previous exposure may explain why 218 
the titres by VMN were markedly higher than for the more recent A(H1N1)pdm09 219 
virus. 220 
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For B(Phuket) the VMN assay GMT was statistically significantly lower than the HAI 221 
titre.  The estimated equivalent VMN titre of HAI 40 was 10.17 (95% CI 7.74-13.36). A 222 
previous study comparing HAI and VMN reported increased rates of seroconversion 223 
by VMN compared with HAI but equivalent GMTs were not reported[23].  Several 224 
previous studies have documented low sensitivity of the HAI assay when using 225 
influenza B virus, which can partially be overcome by ether-treatment of the 226 
antigen[31 ?33]. Ether treatment cleaves the virion and increases Ab binding 227 
sites[32,34] however the virion is rendered unable to replicate and therefore 228 
unsuitable for use in VMN assay.  We used the same egg-grown B(Phuket) virus 229 
batch in both HAI and VMN assays to improve comparability of the data, and applied 230 
antigen modification with ether treatment to the part of the virus batch to be used 231 
in the HAI to optimise assay sensitivity.  This may account for the relative 232 
insensitivity of VMN compared with the HAI in our study. 233 
In this study population, seroconversion by HAI was completely absent for all 3 234 
vaccine components, while the more sensitive ELISA-VMN detected a single 235 
seroconversion in a patient vaccinated within the first 3 months of HSCT.  Pauksen et 236 
al. observed seroconversion rates by HAI to SIIV administered within 12 months 237 
post-HSCT of 31% for A(H1N1), 9% for A(H3N2), and 20% for influenza B.  238 
Conditioning intensity, HSC source and use of lymphocyte depletion were not 239 
reported[12].  Karras et al reported low seroconversion rates of 0% to A(H3N2), 6% 240 
for A(H1N1) and 8% for Influenza B[13].  In this study 44.6% of patients received RIC 241 
and the remainder myeloablative conditioning (MAC) and none received lymphocyte 242 
deplete grafts.  In bone marrow alloHSCT recipients who universally received 243 
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lymphocyte deplete grafts, no seroconversions were reported in the first 6 month 244 
post-HSCT[11].   In our present study, universal in-vivo lymphocyte depletion may 245 
have impacted on vaccine immunogenicity.  Both alemtuzumab and ATG are broadly 246 
immunosuppressive with activity beyond the target T-cell compartment[35], and In 247 
vivo lymphocyte depletion with these agents may contribute to delayed immune 248 
reconstitution and an increased risk of viral infection[36,37]. In the solid organ 249 
transplant setting, a trend towards poorer response to SIIV in patients vaccinated 250 
within a year of receiving ATG has been reported[38].  The median age in our study 251 
was 57.8, compared with 21-40.8 [11,13] in the studies above. Older age is 252 
associated with poorer influenza vaccine immunogenicity in the general population 253 
and this may have been a contributing factor to the poor response in this study 254 
population[39]. 255 
ĞƐƉŝƚĞǀĂĐĐŝŶĂƚŝŽŶ ?ƌĂƚĞƐŽĨƚŝƚƌĞA? ? ?ďǇ,/ǁĞƌĞƐƚĂďůĞĨƌŽŵƉƌĞ- to post-256 
vaccination for A(H3N2) and fell for A(H1N1) and B(Phuket).  Baseline seroprotection 257 
rates were 28.6% for A(H1N1)pdm09, 14.3% for A(H3N2), 32.1% for B(Phuket) and 258 
50% to any 1 or more  strain.  In an immunogenicity study of the monovalent 259 
A(H1N1)pdm09 vaccine, Issa and colleagues reported seroresponse rates to the 260 
ƐƚƵĚǇǀĂĐĐŝŶĞ ?ďƵƚĂůƐŽ,/ƚŝƚƌĞƐA? ? ?ƚŽƚŚĞƐĞĂƐŽŶĂůŝ Ĩ ƵĞŶǌĂƐƚƌĂŝŶƐ ?dŚĞƐĞ261 
ranged from 20.7% for Influenza B to 57.4% for A(H3N2).   However, these patients 262 
were evaluated at 2.5 to 92.7 months post-HSCT, and some had received the 263 
seasonal IIV in previous post-HSCT influenza seasons. In contrast, patients in this 264 
current study were all seasonal IIV naïve following HSCT.  Other studies have 265 
reported baseline seroprotection rates to Influenza A and B of 12-16%[12] and 0-266 
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29%[40].  Pre-ǀĂĐĐŝŶĂƚŝŽŶƌĂƚĞƐŽĨ,/ƚŝƚƌĞA? ? ?ĨĞůůǁŝƚŚƚŝŵĞĨƌŽŵ,^d ? ? ?A?Ăƚ ?-3267 
months, 50% at 3-6 months, 28.6% at 6-12 months) and this is consistent with 268 
previous studies that have reported a waning of disease specific Ab within the first-269 
year post-HSCT.  Although we did not compare pre- with post-HSCT titres, our 270 
findings suggest that pre-HSCT vaccination may be an approach to protecting 271 
recipients during the first few months post-HSCT when they are most vulnerable. A 272 
study  investigating this approach has shown seroresponse rates of 22.9% (H1N1) 273 
and 25%  (H3 and B Ag) when recipients were vaccinatd 10 days pre-HSCT[41].   274 
None of the evaluated patient characteristics correlated with seroresponse 275 
measures or with GMT or GMRs (data not shown). Neither active GvHD nor 276 
concomitant IST correlated with post-ǀĂĐĐŝŶĂƚŝŽŶ,/ƚŝƚƌĞA? ? ? ?Ŷ association 277 
between IST, GvHD and response to influenza vaccination has not been identified 278 
consistently.  Our findings are in agreement with previous studies reporting low 279 
response by HAI in the first 12 months.  While Karras and colleagues suggest that 280 
equivalent seroconversion rates to 1 or more strains at 2-6 and 6-12 months (12 % v 281 
30% p=0.43)[13] may justify early vaccination, our findings of almost entirely absent 282 
humoral response throughout the first year would argue against this strategy in RIC 283 
PBSC lymphocyte deplete alloHSCT recipients.   284 
 285 
Conlusions 286 
In conclusion, this is the first study to use the VMN assay to assess the 287 
immunogenicity of seasonal IIV in HSCT recipients.  The CPE and ELISA VMN detected 288 
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Ab in more serum samples than HAI, and GMTs were statistically significantly higher 289 
by VMN than HAI for A(H1N1)pdm09 and A(H3N2).  However, for influenza B, GMTs 290 
were lower by VMN than an ether-modified HAI.   The ELISA-VMN detected a single 291 
seroconversion to A(H1N1)pdm09.  This limited seroresponse to trivalent SIIV 292 
administered in the first-year post-HSCT in a cohort of RIC PBSC alloHSCT recipients 293 
who underwent in-vivo lymphocyte depletion suggests that a more tailored 294 
approach to vaccination may be desirable, although future studies to define clinical 295 
and immunological predictors of response to vaccine are required.   Furthermore, 296 
there is a clear need for novel immunogenic vaccination schedules and vaccine 297 
formulations in this patient group.  Early phase studies of high-dose seasonal 298 
influenza vaccines have shown promising results[42].  In line with CHMP 299 
recommendations, consideration should be given to using the VMN assay to assess 300 
immunological response to SIIV in such future studies, and combining this with 301 
clinical efficacy data may define seroprotective VMN titres.  The VMN assay may 302 
provide useful data in other immunocompromised patient groups such as recipients 303 
of chemo- or immunotherapies and future studies are warranted.  304 
 305 
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Table 1. Characteristics of n=28 Study Participants  
 
  
Characteristic (n=28) Value 
Age at HSCT, median (range), (IQR) 57.8 (38.0-72.1), (12.7) 
Gender male, n(%) 15 (53.6) 
Diagnosis, n (%)  
Acute lymphoblastic leukaemia (ALL)  3 (10.7) 
Acute myeloid leukaemia (AML) 14 (50.0) 
Chronic lymphocytic leukaemia (CLL) 1 (3.6) 
Chronic myelomonocytic leukaemia (CMML) 1 (3.6) 
Myelodysplastic syndrome (MDS) 4 (14.3) 
Myelofibrosis (MF) 2(7.1) 
Multiple myeloma (MM) 1 (3.6) 
Non-Hodgkin Lymphoma (NHL) 2 (7.1) 
Donor type, n (%)  
Sibling donor 8 (28.6) 
Volunteer unrelated donor (VUD) 20 (71.4) 
Stem cell source, n (%)  
Peripheral blood stem cell (PBSC) 28 (100) 
Conditioning Intensity, n (%)  
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Reduced intensity 28 (100) 
Lymphocyte depletion, n (%)  
Alemtuzumab 25 (89.3) 
Antithymocyte globulin (ATG) 3 (10.7) 
Days from HSCT to vaccination, median (range), (IQR) 78.5 (24-363), (136) 
Months from HSCT to vaccination, n (%)  
0-3 15(53.6) 
>3-6 6 (21.4) 
>6-12 7 (25) 
Lymphocyte count (x10^9) at vaccination, median (range), (IQR) 0.57 (0.02-2.98),(0.63) 
Graft versus host disease at vaccination, n(%) 8 (28.6) 
Acute (stage 1, skin) 5 (17.9) 
Chronic (mild, skin) 3 (10.7) 
Immunosuppressive therapy (IST) at vaccination, n(%)  
Any IST 18 (64.3) 
Single agent 13 (46.4) 
Dual agent 4 (14.3) 
Triple agent 1 (3.6) 
Intravenous Immunoglobulin (IVIg) in last 12 months, n(%) 2 (7.1) 
Rituximab in last 12 months, n(%) 3 (10.7) 
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Table 2. Geometric Mean Titres (GMT), Geometric Mean Ratios (GMR), percentage of seroconversions and percentage 
ŽĨƚŝƚƌĞƐA䠃? ?ŽĨ ?, ?E ? ?ƉĚŵ ? ? ? ?H3N2) and B(Phuket) antibodies by Haemagglutination (HAI) and Virus 
Microneutralisation (VMN) assays.  Value (95% Confidence interval). 
 Vaccine Component 
 A(H1N1)pdm09 A(H3N2) B(Phuket) 
HAI       
GMT pre-vaccination  12.65 (7.94-21.67) 11.46 (7.76-18.05) 15.17 (9.31-35.41) 
GMT post-vaccination 11.45 (7.44-19.06) 11.60 (8.07-17.89) 11.89 (7.54-20.50) 
GMR 0.91 (0.78-1.03) 1.01 (0.93-1.11) 0.78(0.62-0.94) 
% seroconversion 0 0 0 
% Pre-ǀĂĐĐŝŶĂƚŝŽŶ,/A? ? ? 28.6 (8) 14.3 (4) 32.1 (9) 
% Post sĂĐĐ,/A? ? ? 25.0 (7) 14.3 (4) 25.0 (7) 
CPE-VMN       
GMT pre-vaccination 16.82 (9.26-33.22) 129.64(70.62-241.87) 6.98 (5.54-9.14) 
GMT post-vaccination 16.41 (9.76-30.55) 118.88 (67.68-212.68) 6.25 (5.20-7.69) 
GMR 0.98  (0.82-1.17) 0.92  (0.74-1.11) 0.89 (0.82-0.96) 
% seroconversion 0 0 0 
ELISA-VMN       
GMT pre-vaccination 34.43 (16-85-75.68)   
GMT post-vaccination 32.87 (16.80-68.49)   
GMR 0.95 (0.74-1.11)   
% seroconversion 3.6 (1)   
 464 
 465 
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Table 3. Proportion of patients with pre and post-vaccination haemagglutination 
ŝŶŚŝďŝƚŝŽŶ ?,/ ?ĂŶƚŝďŽĚǇ ?ď ?ƚŝƚƌĞƐA? ? ? 
    
Vaccine Component 
Vaccination 
timepoint, 
months 
Pre-Vaccination 
ƚŝƚƌĞƐA? ? ? ?Ŷ ?A㤃? 
Post-Vaccination,  
A? ? ? ?Ŷ ?A㤃? 
A(H1N1)pdm09 <3 (n=15) 5 (33.3) 4 (26.7) 
 3-6 (n=6) 2 (33.3) 2 (33.3) 
 6-12 (n=7) 1 (14.3) 1 (14.3) 
  Total  8 (28.6) 7 (25.0) 
A(H3N2) <3 (n=15) 2 (13.3) 2 (13.3) 
 3-6 (n=6) 1 (16.7) 1 (16.7) 
 6-12 (n=7) 1 (14.3) 1 (14.3) 
  Total 4 (14.3) 4 (14.3) 
B(Phuket) <3 (n=15) 6 (40.0) 4 (26.7) 
 3-6 (n=6) 1 (16.7) 1 (16.7) 
 6-12 (n=7) 2 (28.6) 2 (28.6) 
  Total 9 (32.1) 7(25.0) 
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A?ĂŶǇŽŶĞǀĂĐĐŝŶĞ
component 
<3 (n=15) 9 (60.0) 9 (60.0) 
 3-6 (n=6) 3 (50.0) 3 (50.0) 
 6-12 (n=7) 2 (28.6) 2 (28.6) 
  Total 14 (50) 14 (50.0) 
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